title: Cardiovascular adverse effects of newer antidepressants.
abstract: Newer antidepressants that are more selective in their neurotransmitter effects include the selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and others (agomelatine, bupropion, mirtazapine, reboxetine, vilazodone, vortioxetine). This article systematically reviews data from a variety of sources regarding the potential adverse effects of these medications on various cardiovascular parameters. Potential biochemical mechanisms by which these antidepressants may adversely affect the cardiovascular system are also discussed. Antidepressants that are associated with higher cardiovascular risk (SNRIs, reboxetine), lower risk (SSRIs), and without current evidence of cardiovascular risk (agomelatine, mirtazapine, vilazodone, vortioxetine) are identified. The FDA's recommendations regarding citalopram are organized and summarized, and situations with higher risk of cardiovascular adverse effects are identified.
authors.affiliation: Department of Psychiatry and Human Behavior, Mood Disorders Program, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Rajnish
authors.initials: R
authors.lastname: Mago
authors.forename: Neeta
authors.initials: N
authors.lastname: Tripathi
authors.forename: Chittaranjan
authors.initials: C
authors.lastname: Andrade
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D016239:MEDLINE / Q000706:statistics & numerical data
chemical_list: D000928:Antidepressive Agents